Trial of Lixisenatide in Early Parkinson’s Disease
New England Journal of Medicine · 04.04.2024 · 390 (13) · 1176-1185
DOI: 10.1056/nejmoa2312323 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 04.04.2024. Verfasst von Wassilios G Meissner und 44 weiteren Autor:innen. Beteiligte Einrichtung: From the French Clinical Research Network (F-CRIN) for Parkinson's Disease and Movement Disorders (NS-Park-F-CRIN) (W.G.M., P.R., C. Giordana, D.M., …. Hauptthemen laut MEDLINE: Antiparkinson Agents, Parkinson Disease, Peptides, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 378-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Cure Parkinson’s, French Ministry of Health - PHRC-N.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the French Clinical Research Network (F-CRIN) for Parkinson's Disease and Movement Disorders (NS-Park-F-CRIN) (W.G.M., P.R., C. Giordana, D.M., P. Derkinderen, J.-L.H., M.A., I.B., T.B., C.B.-C., N.C., O.C., J.-C.C…
ORCID-Profile: Philippe Damier, Stéphane Grimaldi, Richard K Wyse
Förderung
- Cure Parkinson’s
- French Ministry of Health - PHRC-N
Zitieren
APA
Meissner, W. G., Remy, P., Giordana, C., Maltête, D., Derkinderen, P., Houéto, J. L., Anheim, M., Benatru, I., Boraud, T., Brefel-Courbon, C., Carrière, N., Catala, H., Colin, O., Corvol, J. C., Damier, P., Dellapina, E., Devos, D., Drapier, S., Fabbri, M., …, & LIXIPARK Study Group (2024). Trial of Lixisenatide in Early Parkinson’s Disease. New England Journal of Medicine, 390(13), 1176-1185. https://doi.org/10.1056/nejmoa2312323
Vancouver
Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto JL, et al. Trial of Lixisenatide in Early Parkinson’s Disease. New England Journal of Medicine. 2024;390(13):1176-1185. doi:10.1056/nejmoa2312323
BibTeX
@article{Meissner2024,
author = {Meissner, Wassilios G and Remy, Philippe and Giordana, Caroline and Maltête, David and Derkinderen, Pascal and Houéto, Jean-Luc and Anheim, Mathieu and Benatru, Isabelle and Boraud, Thomas and Brefel-Courbon, Christine and Carrière, Nicolas and Catala, Hélène and Colin, Olivier and Corvol, Jean-Christophe and Damier, Philippe and Dellapina, Estelle and Devos, David and Drapier, Sophie and Fabbri, Margherita and Ferrier, Vanessa and Foubert-Samier, Alexandra and Frismand-Kryloff, Solène and Georget, Aurore and Germain, Christine and Grimaldi, Stéphane and Hardy, Clémence and Hopes, Lucie and Krystkowiak, Pierre and Laurens, Brice and Lefaucheur, Romain and Mariani, Louise-Laure and Marques, Ana and Marse, Claire and Ory-Magne, Fabienne and Rigalleau, Vincent and Salhi, Hayet and Saubion, Amandine and Stott, Simon R W and Thalamas, Claire and Thiriez, Claire and Tir, Mélissa and Wyse, Richard K and Benard, Antoine and Rascol, Olivier and LIXIPARK Study Group, LIXIPARK Study Group},
title = {Trial of Lixisenatide in Early Parkinson’s Disease},
journal = {New England Journal of Medicine},
year = {2024},
volume = {390},
number = {13},
pages = {1176--1185},
doi = {10.1056/nejmoa2312323}
}
EUVIMED